No.16-61 August 26, 2016

ANTICANCER AGENT "TREAKISYM® FOR INJECTION 100 MG" APPROVED IN JAPAN FOR ADDITIONAL INDICATION OF CHRONIC LYMPHOCYTIC LEUKEMIA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the anticancer agent TREAKISYM® for Injection 100 mg (generic name: bendamustine hydrochloride, "TREAKISYM") has been approved in Japan for an additional indication of chronic lymphocytic leukemia. TREAKISYM is the subject of a licensing agreement concluded between Eisai and SymBio Pharmaceuticals Limited (Headquarters: Tokyo, President & CEO: Fuminori Yoshida, "SymBio").

TREAKISYM was initially approved in Japan in October 2010 for relapsed or refractory low-grade B-cell non-Hodgkin′s lymphoma and mantle cell lymphoma. Under the licensing agreement concluded between the two companies, Eisai has been marketing the product in Japan since its launch in December 2010.

Symbio filed an application for this add(t)11(s)-8(3(k)-20(u. 8)).434aoa13 Tw 0.723 1Tw 0.723 1Tw 0.723 1TwTd ( )2((

[Notes to editors]

1. About bendamustine hydrochloride (generic name, product name: TREAKISYM)

Bendamustine hydrochloride is an anticancer agent originally synthesized by